Formulating for the Future of Transplant Patient Therapy

Veloxis is a specialty pharmaceutical company committed to improving the lives of transplant patients. Our unique, patented delivery technology, MeltDose®, is designed to enhance the absorption and bioavailability of select orally administered drugs.

Veloxis is an international company with headquarters in Hørsholm, Denmark, and a fully owned subsidiary in Edison, New Jersey, USA.


Nov 12, 2015
Conference Call Announcing Interim Report for the Third Quarter 2015

Webcast Webcast
PDF Q3 2015 Interim Report
 766.5 KB   Add to Briefcase
PDF Q3 2015 Presentation
 470.2 KB   Add to Briefcase

UK: +44(0)20 7136 2055
US: +1718 354 1359
Denmark: +4538 48 75 13
Start time: 3:00 pm CET
Please dial in for your pre-conference 30 prior to the scheduled start time.
Confirmation Code:  1720884


Stock Information